More than 4,000 independent pharmacists gathered at the Cardinal Health RBC 2026 conference in Orlando this week, and one story from that gathering deserves far more attention than a conference recap. Iowa’s first pharmacist-led walk-in clinic opened this year. It is already being recognized as a model for what community pharmacy’s next chapter looks like. And the business architecture behind it solves the precise economic problem that has strangled independent pharmacy for a decade.
The Problem This Model Solves
The walk-in clinic model decouples revenue from prescription volume. That sentence contains the entire economic argument.
Every pharmacist reading this newsletter understands the dispensing revenue trap: the pharmacy earns money when a prescription is dispensed. The margin on each prescription is determined by forces the pharmacist does not control, including PBM reimbursement rates, drug acquisition costs, and the gap between the two. Prescription volume growth does not reliably produce profit growth when margin compression is running faster than volume increases. The 300 closures in 90 days reported in this newsletter’s prior issue reflect the endpoint of that trap for pharmacies that never built a second revenue stream.
The walk-in clinic model generates revenue when a patient receives a clinical service, regardless of whether a prescription results. A patient who presents with strep throat symptoms, receives a rapid strep test, gets a positive result, and receives a prescription generates testing revenue, evaluation revenue, and dispensing revenue. A patient who presents with a UTI, receives a clinical assessment, and is treated under a standing order generates evaluation and dispensing revenue. A patient who comes in for an A1C test and chronic disease management counseling generates testing and counseling revenue with no dispensing component at all.
The clinical service revenue is not subject to PBM reimbursement compression. It is billed under medical CPT codes, through Medicare Part B and commercial health plan medical benefits, at rates that reflect the clinical value of the service rather than the commodity price of the drug. That billing structure is the foundation of a pharmacy financial model that can survive the reimbursement environment that is closing dispensing-only pharmacies.
The Iowa Pioneer and What His Recognition Signals
The pharmacist recognized at RBC 2026 for opening Iowa’s first pharmacist-led walk-in clinic received specific honor for bringing affordable, collaborative care closer to patients in his community. The RBC award structure, which spotlights scalable models for collaborative care, medication management simplification, and mentorship, signals that the independent pharmacy community is actively choosing to celebrate the pharmacists who are building toward the profession’s survival rather than those who have most efficiently managed its current model.
That cultural signal matters. The pharmacists winning recognition at the profession’s largest independent pharmacy conference are not the ones who dispense the most volume or the most efficiently. They are the ones who built something new. Iowa’s walk-in clinic pharmacist built something that had not existed in Iowa before. He did it in a regulatory environment, clinical service reimbursement landscape, and operational context that every other Iowa pharmacist operates in. The regulatory path is the same. The clinical training is the same. The difference is the decision to build.
The Harps Model as the Scalability Proof
Also featured at RBC 2026, Harps Food Stores’ clinical service model provides the evidence that the walk-in clinic approach is not a single pharmacy’s exceptional story. It is a scalable business model.
Harps pharmacists now provide test-and-treat services for strep and flu, oral contraceptive prescribing, A1C testing, and Medicare Part B-billed vaccines across all 39 locations in Arkansas, Missouri, and Oklahoma. A regional grocery chain with 39 locations building Medicare Part B billing infrastructure across its entire pharmacy network is not a boutique experiment. It is a regional clinical network demonstrating that pharmacist-led clinical services can be standardized, credentialed, billed, and sustained at a scale that generates real financial results.
The Harps implementation story, covered in this newsletter’s Total Pharmacy Solutions Summit issue, describes the cultural and operational arc every pharmacy faces when implementing new clinical services. Change is always initially difficult. Staff resistance is predictable. The pharmacies that built competency systematically, service by service, and built billing infrastructure before scaling patient volume, are the ones that can now describe clinical programs their staff would never want to give up.
The key economic metric that Harps and the Iowa walk-in clinic both demonstrate: Medicare Part B billing transforms a clinical service from a cost center or marketing activity into a revenue center. Point-of-care testing billed under CPT codes for A1C, lipid panels, and glucose generates reimbursable clinical encounters that stand independent of whether a Part D prescription follows. Vaccine administration billed under Part B generates professional service revenue on top of the vaccine product itself. The billing infrastructure is the financial foundation that makes the clinical model sustainable.
The Mike Nabolsi Story: Advocacy as Business Strategy
Mike Nabolsi, PharmD, of Warriors Pharmacy in Detroit, earned the inaugural Cardinal Health Advocacy Award at RBC 2026, recognition for a pharmacist who turned advocacy into a concrete outcome for his community.
Warriors Pharmacy’s story is one of a neighborhood pharmacy that decided its survival depended on being irreplaceable, not in cost, but in service, and built that irreplaceability through clinical relationships with the community it serves. Detroit’s communities present the access challenges that characterize the pharmacy desert geography this newsletter documented earlier in the year: patients who are geographically closer to a pharmacy than to a physician’s office, who face barriers to specialty care and consistent primary care follow-up, and who visit the pharmacy with a frequency and trust level that no other healthcare touchpoint matches.
The advocacy work that earned Nabolsi the inaugural award translates directly into business strategy. A pharmacist who advocates for expanded pharmacist scope in their state, builds the legislative relationships that support the Main Street Pharmacy Access Act and Standard of Care reform, and participates in their state pharmacy association’s lobbying infrastructure is not performing civic charity. They are building the regulatory environment in which their pharmacy’s clinical service programs can be legally authorized, reimbursed, and sustainably operated. The advocacy is the business development work, conducted years before the revenue arrives.
The Cardinal Health Advocacy Award, specifically described as inaugural, signals that the conference’s leadership is consciously elevating advocacy as a recognized professional achievement rather than a peripheral activity for pharmacists with political interests. The profession is choosing to recognize the pharmacists who build the policy environment that makes the clinical models viable.
The Walk-In Clinic Model: What It Requires Specifically
The walk-in clinic does not require a new building. It requires a defined clinical space within the existing pharmacy, a CLIA certificate of waiver for point-of-care testing, a billing infrastructure for medical CPT codes under Part B and commercial health plans, and a clinical service menu built around the pharmacist’s training and the community’s health needs.
The regulatory foundation varies by state and determines the specific services available without prescriber involvement. In states with broad collaborative practice agreement authority or Standard of Care frameworks, covered in this newsletter’s prior issue, the walk-in clinical menu can include test-and-treat protocols for strep, UTI, influenza, and other minor acute illnesses under pharmacist authority with appropriate documentation. In states with more restrictive practice acts, a physician collaborative practice agreement establishes the clinical protocols under which the pharmacist operates.
The clinical service sequence that builds a sustainable walk-in clinic model generally follows the Harps pattern: start with what is already authorized and billable, which in most states includes point-of-care testing and vaccine administration under Part B, then add test-and-treat services as state-specific authority is confirmed, then add chronic disease management visits and medication therapy management under the CMS billing codes that support those encounters.
The CLIA certificate of waiver is the enabling document for most point-of-care testing services. As covered in this newsletter’s Summer Lull issue, the CLIA application takes six to twelve weeks for state review. A pharmacy that submits the application in August is eligible for CLIA-waived testing by October or November, in time for the fall respiratory illness season that drives the highest demand for strep and flu testing.
The Medicare Part B enrollment, required to bill vaccine administration and point-of-care testing directly to Medicare, requires pharmacy enrollment as a provider under Part B, separate from Part D dispensing enrollment. The enrollment process requires a CMS Form 855B and takes eight to twelve weeks for CMS processing. Both the CLIA application and the Part B enrollment are applications that can be initiated this week for pharmacies that have not yet completed them.
The RBC 2026 Policy Context
The Cardinal Health RBC 2026 conference policy emphasis reinforced the same priorities this newsletter has tracked across 2026: federal and state efforts to expand reimbursement and access for pharmacist-provided clinical services, scalable models for collaborative care, and the mentorship infrastructure that allows the profession’s innovators to teach their models to peers who are building next.
The walk-in clinic model is not the only structure capable of producing these outcomes. The NCPA Stroke Belt cardiovascular screening program produced 11,188 encounters in six months across 25 pharmacies through a network model rather than a dedicated clinical space. The CMS ACCESS Model creates a coordination payment structure that doesn’t require walk-in appointments at all. The RPM billing codes create clinical revenue from remote monitoring without physical patient visits.
What the Iowa walk-in clinic and the Harps network share with all those models is the common financial principle: clinical revenue generated independent of dispensing volume is the structural solution to margin compression driven by PBM reimbursement. The specific delivery model varies. The financial principle is universal.
Your Action This Week
Research your state’s current regulatory framework for pharmacist-operated walk-in clinics. Three specific questions produce the information you need to begin building.
First, does your state pharmacy practice act allow pharmacists to initiate treatment for minor acute illnesses independently, under a collaborative practice agreement, or not at all without individual prescriptions? The answer determines whether you can offer test-and-treat services without a physician agreement and what the collaborative practice agreement needs to specify if one is required.
Second, do you hold a current CLIA certificate of waiver? If not, download CMS Form 116 from cms.gov and begin the application this week. Six to twelve weeks of processing time means an August application produces October or November authorization, in time for respiratory illness season.
Third, are you enrolled as a provider under Medicare Part B? If not, the CMS Form 855B initiates that enrollment. Part B enrollment allows direct billing for vaccine administration and point-of-care testing services, creating the Medicare revenue stream that both the Iowa walk-in clinic and the Harps network depend on.
If a collaborative practice agreement is required in your state, identify one physician in your area willing to co-sign one and schedule a meeting. The agreement doesn’t need to be complex. It needs to define the clinical conditions the pharmacist can treat, the protocols governing treatment decisions, and the conditions requiring physician referral. Many state pharmacy associations have template CPA agreements available to members.
The walk-in clinic model doesn’t require a new building. It requires a dedicated clinical schedule, a CLIA certificate, a Part B billing setup, and the willingness to be the pharmacist who built something new in your community.
Iowa has one now. Your state doesn’t have to wait for someone else to be the first.
Sources: Drug Topics (Cardinal Health RBC 2026 Coverage: Iowa’s First Pharmacist Walk-In Clinic and Advocacy Award, August 2026), Drug Topics (Harps Food Stores Clinical Services Model: RBC 2026 Feature), Cardinal Health RBC 2026 Official Coverage (Conference Awards and Policy Priorities), Drug Topics (Total Pharmacy Solutions Summit: Harps Food Stores Jennifer Griffin and Duane Jones Interview, August 2026), CMS (CLIA Application Form 116 and Certificate of Waiver Overview), CMS (Medicare Part B Provider Enrollment Form 855B), NASPA (State Pharmacist Scope of Practice: Test-and-Treat Authority by State, 2026 Update), Pharmacy Times (Standard of Care Regulatory Reform: Idaho Model and State Legislative Landscape, August 2026)